NASDAQ:RAPT RAPT Therapeutics (RAPT) Stock Price, News & Analysis → The new masters of energy (From Porter & Company) (Ad) Free RAPT Stock Alerts $3.84 -0.19 (-4.71%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$3.83▼$4.0150-Day Range$3.84▼$9.3852-Week Range$3.82▼$27.35Volume365,096 shsAverage Volume1.08 million shsMarket Capitalization$134.02 millionP/E RatioN/ADividend YieldN/APrice Target$24.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get RAPT Therapeutics alerts: Email Address RAPT Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.31 Rating ScoreUpside/Downside542.4% Upside$24.67 Price TargetShort InterestHealthy8.91% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.93) to ($2.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.10 out of 5 starsMedical Sector128th out of 905 stocksPharmaceutical Preparations Industry50th out of 430 stocks 4.2 Analyst's Opinion Consensus RatingRAPT Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 4 buy ratings, 9 hold ratings, and no sell ratings.Amount of Analyst CoverageRAPT Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about RAPT Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.91% of the outstanding shares of RAPT Therapeutics have been sold short.Short Interest Ratio / Days to CoverRAPT Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in RAPT Therapeutics has recently decreased by 3.42%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRAPT Therapeutics does not currently pay a dividend.Dividend GrowthRAPT Therapeutics does not have a long track record of dividend growth. Previous Next 3.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRAPT Therapeutics has received a 44.02% net impact score from Upright. Rapt Therapeutics seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for RAPT Therapeutics is -0.81. Previous Next 0.6 News and Social Media Coverage Search Interest7 people have searched for RAPT on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added RAPT Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, RAPT Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.60% of the stock of RAPT Therapeutics is held by insiders.Percentage Held by Institutions99.09% of the stock of RAPT Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about RAPT Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for RAPT Therapeutics are expected to grow in the coming year, from ($2.93) to ($2.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RAPT Therapeutics is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RAPT Therapeutics is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRAPT Therapeutics has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about RAPT Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe new masters of energyAccording to one source, this new grid could soon provide energy to “one billion people in the world who don’t have access to electricity right now.” And early investors could make a fortune.Click here to get all the details. About RAPT Therapeutics Stock (NASDAQ:RAPT)RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb CompanyRead More RAPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RAPT Stock News HeadlinesMay 20, 2024 | seekingalpha.comRAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric OpportunityMay 14, 2024 | msn.comWolfe downgrades RAPT, but still sees "immense" upside potentialMay 12, 2024 | finance.yahoo.comHere's Why We're Watching RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn SituationMay 11, 2024 | msn.comRAPT terminates Phase II trials for lead candidate following clinical holdMay 11, 2024 | msn.comBarclays Downgrades RAPT Therapeutics (RAPT)May 10, 2024 | markets.businessinsider.comMaintaining Hold Rating on RAPT Therapeutics Amid Clinical Uncertainties and Financial OutlookMay 10, 2024 | msn.comRAPT falls for second day as Guggenheim, Barclays downgrade stockMay 10, 2024 | finance.yahoo.comRAPT Therapeutics Inc. Reports Q1 2024 Earnings: A Detailed Financial OverviewMay 9, 2024 | morningstar.comRAPT Therapeutics Shares Hit 52-Week Low After Trials ClosedMay 9, 2024 | finance.yahoo.comRAPT Therapeutics Shares Plunge After Wider Q1 Loss, Closing of Zelnecirnon TrialsMay 9, 2024 | finance.yahoo.comWhat's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?May 9, 2024 | investorplace.comRAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q1 2024May 9, 2024 | globenewswire.comRAPT Therapeutics Reports First Quarter 2024 Financial ResultsApril 12, 2024 | markets.businessinsider.comHold Rating on RAPT Therapeutics Amid Promising Data and Regulatory UncertaintiesApril 11, 2024 | investing.comRAPT reports positive phase 2 cancer trial resultsApril 10, 2024 | markets.businessinsider.comMaintaining Hold Rating on RAPT Therapeutics Amidst Mixed Clinical Results and Regulatory UncertaintyApril 9, 2024 | globenewswire.comRAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer PatientsApril 9, 2024 | investorplace.com3 Biotech Stocks to Dump Before They Go to ZeroMarch 16, 2024 | finance.yahoo.comRAPT Apr 2024 10.000 putMarch 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPTMarch 11, 2024 | markets.businessinsider.comHold Rating on RAPT Therapeutics Amid Clinical Trial Uncertainties and Financial ConcernsMarch 8, 2024 | finance.yahoo.comRAPT Oct 2024 5.000 callMarch 7, 2024 | investorplace.comRAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023March 7, 2024 | globenewswire.comRAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 5, 2024 | globenewswire.comRAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual MeetingSee More Headlines Receive RAPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RAPT Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/07/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RAPT CUSIPN/A CIK1673772 Webwww.rapt.com Phone(650) 489-9000FaxN/AEmployees126Year Founded2015Price Target and Rating Average Stock Price Target$24.67 High Stock Price Target$41.00 Low Stock Price Target$4.00 Potential Upside/Downside+542.4%Consensus RatingHold Rating Score (0-4)2.31 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($3.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-116,800,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-72.61% Return on Assets-62.99% Debt Debt-to-Equity RatioN/A Current Ratio7.01 Quick Ratio7.01 Sales & Book Value Annual Sales$1.53 million Price / Sales87.59 Cash FlowN/A Price / Cash FlowN/A Book Value$4.27 per share Price / Book0.90Miscellaneous Outstanding Shares34,900,000Free Float32,599,000Market Cap$134.02 million OptionableOptionable Beta0.40 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Brian Russell Wong M.D. (Age 52)Ph.D., CEO, President & Director Comp: $861.24kMr. Rodney K. B. Young (Age 61)CFO, Principal Accounting Officer & Secretary Comp: $616.56kDr. William Ho M.D. (Age 58)Ph.D., Chief Medical Officer Comp: $620.32kSteve Young Ph.D.Vice President of TechnologyDr. Dirk G. Brockstedt Ph.D. (Age 55)Chief Scientific Officer Comp: $490.25kMr. Michael ListgartenGeneral CounselMs. Gwen R. Carscadden (Age 63)Chief Human Resources Officer Dr. Paul Kassner (Age 57)Senior Vice President of Quantitative & Computational Biology Dr. David Wustrow (Age 65)Senior Vice President of Drug Discovery & Preclinical Development Ms. Jennifer NicholsonSenior Vice President of Regulatory Affairs & Quality AssuranceMore ExecutivesKey CompetitorsHeron TherapeuticsNASDAQ:HRTXSIGA TechnologiesNASDAQ:SIGAY-mAbs TherapeuticsNASDAQ:YMABCOMPASS PathwaysNASDAQ:CMPSAltimmuneNASDAQ:ALTView All CompetitorsInsiders & InstitutionsIkarian Capital LLCBought 187,400 shares on 5/17/2024Ownership: 0.000%Kingdon Capital Management L.L.C.Bought 534,172 shares on 5/16/2024Ownership: 4.298%Redmile Group LLCBought 295,622 shares on 5/16/2024Ownership: 1.898%Affinity Asset Advisors LLCBought 577,100 shares on 5/15/2024Ownership: 0.000%Torno Capital LLCBought 4,500 shares on 5/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions RAPT Stock Analysis - Frequently Asked Questions Should I buy or sell RAPT Therapeutics stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last year. There are currently 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RAPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RAPT, but not buy additional shares or sell existing shares. View RAPT analyst ratings or view top-rated stocks. What is RAPT Therapeutics' stock price target for 2024? 13 brokers have issued 12 month price objectives for RAPT Therapeutics' shares. Their RAPT share price targets range from $4.00 to $41.00. On average, they predict the company's stock price to reach $24.67 in the next year. This suggests a possible upside of 542.4% from the stock's current price. View analysts price targets for RAPT or view top-rated stocks among Wall Street analysts. How have RAPT shares performed in 2024? RAPT Therapeutics' stock was trading at $24.85 at the beginning of the year. Since then, RAPT shares have decreased by 84.5% and is now trading at $3.84. View the best growth stocks for 2024 here. When is RAPT Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our RAPT earnings forecast. How were RAPT Therapeutics' earnings last quarter? RAPT Therapeutics, Inc. (NASDAQ:RAPT) released its quarterly earnings results on Thursday, May, 9th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.78) by $0.01. What is Brian Wong's approval rating as RAPT Therapeutics' CEO? 8 employees have rated RAPT Therapeutics Chief Executive Officer Brian Wong on Glassdoor.com. Brian Wong has an approval rating of 100% among the company's employees. This puts Brian Wong in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of RAPT Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other RAPT Therapeutics investors own include NVIDIA (NVDA), Boeing (BA), Slack Technologies (WORK), Overstock.com (OSTK), Salesforce (CRM), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Livongo Health (LVGO), Mastercard (MA) and QUALCOMM (QCOM). When did RAPT Therapeutics IPO? RAPT Therapeutics (RAPT) raised $39 million in an initial public offering (IPO) on Thursday, October 31st 2019. The company issued 3,000,000 shares at a price of $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank served as the underwriters for the IPO. Who are RAPT Therapeutics' major shareholders? RAPT Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.16%), Price T Rowe Associates Inc. MD (5.81%), Kingdon Capital Management L.L.C. (4.30%), Redmile Group LLC (1.90%), Affinity Asset Advisors LLC (0.00%) and Ikarian Capital LLC (0.00%). Insiders that own company stock include Dirk G Brockstedt, Dirk G Brockstedt, Gino Dellomo, Group Ii Lp Column, Phuong Y Phillips, Rodney Kb Young, Wendye Robbins and William Ho. View institutional ownership trends. How do I buy shares of RAPT Therapeutics? Shares of RAPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RAPT) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RAPT Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RAPT Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.